NCT02775435View on ClinicalTrials.gov

A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407)

PHASE3CompletedINTERVENTIONAL
Enrollment

559

Participants

Timeline

Start Date

June 9, 2016

Primary Completion Date

April 3, 2018

Study Completion Date

September 14, 2023

Conditions
Non-small Cell Lung Cancer
Interventions
BIOLOGICAL

Pembrolizumab

IV infusion

DRUG

Paclitaxel

IV infusion

DRUG

Nab-paclitaxel

IV infusion

DRUG

Carboplatin

IV infusion Carboplatin dose should not to exceed 900 mg.

DRUG

Saline placebo for pembrolizumab

IV infusion

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT02775435 - A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407) | Biotech Hunter | Biotech Hunter